To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.

Condition	Treatment or Intervention	Phase
Amphetamine-Related Disorders	Drug: Lobeline	Phase I

Further Study Details: 

Expected Total Enrollment:  8

The primary objective of this study is to characterize the pharmacoiinetics of three ascending doses of lobeline in normal volunteers.

Ages Eligible for Study:  18 Years   -   45 Years,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Inclusion Criteria:

• Healthy individuals with a body mass index between 18 and 30.
• Willing and able to give written consent.
• Must have a negative drug test
• Females must have a negative pregnancy test piror to study drug administration
• Must have no medical contraindications as determined by routine testing

Exclusion Criteria:

• Please contact the site for more information

California
      U of CA, San Francisco, San Francisco,  California,  94143,  United States

Study chairs or principal investigators

Reese Jones, M.D.,  Principal Investigator,  Langley Porter Psychiatric Institute   

Study ID Numbers:  NIDA-CPU-0007-1
Record last reviewed:  December 2004
Last Updated:  February 16, 2005
Record first received:  December 22, 2004
ClinicalTrials.gov Identifier:  NCT00100074
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08